Lilly's Oral GLP-1 Launch
- The FDA approved Eli Lilly's once-daily oral obesity pill Foundayo under the National Priority Voucher Program. - Early reports say Foundayo was prescribed more than 1,000 times in its first days on the market. - Uptake may hinge less on efficacy and more on payers and distribution, as insurer coverage is narrowing and new channels like Amazon emerge. ( )
Eli Lilly’s new obesity pill Foundayo is off to a fast start, but its rollout is turning on insurance rules and delivery channels as much as the drug itself. (lilly.com, pharmexec.com) The Food and Drug Administration approved Foundayo, the brand name for orforglipron, on April 1 for adults with obesity or adults who are overweight and have at least one weight-related condition. The agency said the decision came 50 days after filing and 294 days before the original January 20, 2027 target date. (fda.gov, accessdata.fda.gov) Foundayo is a glucagon-like peptide-1, or GLP-1, pill, a class of medicines that helps people eat less by slowing digestion and affecting appetite signals. Lilly said it is the only approved weight-loss GLP-1 pill that can be taken any time of day without food or water restrictions. (lilly.com, accessdata.fda.gov) In Lilly’s ATTAIN-1 trial, adults on the highest dose lost an average of 27 pounds, according to the company’s approval announcement. The Food and Drug Administration label carries a boxed warning about thyroid C-cell tumors and says the drug should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (lilly.com, accessdata.fda.gov) Early demand was measurable within days. Pharmaceutical Executive, citing Reuters and IQVIA data, reported 1,390 prescriptions in the first week based on two days of captured data ending April 10. (pharmexec.com) Lilly began taking prescriptions immediately after approval, started shipping on April 6, and said on April 9 that the pill was available through LillyDirect, telehealth providers, and retail pharmacies nationwide. Lilly also said commercial coverage could bring the price down to $25 a month, while self-pay pricing starts at $149 a month. (lilly.com, lilly.com) Amazon moved into that launch window on April 9, saying Amazon Pharmacy would offer Foundayo with same-day delivery in eligible cities, real-time availability, and automatic application of manufacturer coupons. Amazon said insured patients could pay as little as $25 a month and cash-pay customers $149 a month. (marketscreener.com) Coverage is tightening even as new products arrive. NPR reported on April 22 that some employers and insurers are pulling back coverage for obesity drugs such as Wegovy and Zepbound because of cost, leaving patients to navigate prior authorization, exclusions, or cash pay. (npr.org) That leaves Lilly trying to solve two problems at once: getting a newly approved pill onto pharmacy shelves and getting it onto insurance formularies. The first days suggest doctors will write scripts quickly; the next few months will show how many plans will pay for them. (lilly.com, pharmexec.com, npr.org)
